Cost-Effectiveness of Ivacaftor Therapy for Treatment of Cystic Fibrosis Patients With the G551D Gating Mutation
Authors:
- 1 October 2020
- journal article
- research article
- Published by Elsevier in Value in Health
- Vol. 23 (10) , 1332-1339
Abstract
No abstract availableKeywords
Funding Information
- Institute for Clinical and Economic Review
This publication has 23 references indexed in Scilit:
- The Cost Effectiveness of Dry Powder Antibiotics for the Treatment of Pseudomonas aeruginosa in Patients with Cystic FibrosisPharmacoEconomics, 2013
- Survival Benefit of Lung Transplant for Cystic Fibrosis since Lung Allocation Score ImplementationAmerican Journal of Respiratory and Critical Care Medicine, 2013
- Risk factors for rate of decline in FEV1 in adults with cystic fibrosisJournal of Cystic Fibrosis, 2012
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationNew England Journal of Medicine, 2011
- Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective: The ISPOR Drug Cost Task Force Report—Part IIValue in Health, 2010
- Genetic Determinants and Epidemiology of Cystic Fibrosis–Related DiabetesDiabetes Care, 2008
- Risk Factors For Rate of Decline in Forced Expiratory Volume in One Second in Children and Adolescents with Cystic FibrosisThe Journal of Pediatrics, 2007
- Work disability in adults with cystic fibrosis and its relationship to quality of lifeJournal of Cystic Fibrosis, 2007
- Exacerbations in cystic fibrosis {middle dot} 1: Epidemiology and pathogenesisThorax, 2007
- Measuring the Quality of Life Before and After Bilateral Lung Transplantation in Patients With Cystic FibrosisChest, 1994